Olmesartan Vocate (Olmesartan Medoxomil)

Olmesartan Vocate is an angiotensin II receptor blocker used to manage conditions related to the renin‑angiotensin system.

• Hypertension: reduces systolic and diastolic blood pressure in adults with primary hypertension.
• Cardiovascular risk reduction: lowers the risk of stroke and myocardial infarction in patients with hypertension and additional risk factors.
• Diabetic nephropathy: slows progression of kidney disease in adults with type 2 diabetes and hypertension.

• Olmesartan medoxomil is a prodrug that is rapidly hydrolyzed to olmesartan, which selectively blocks the angiotensin II type 1 (AT1) receptor. By preventing angiotensin II from binding, it inhibits vasoconstriction, aldosterone release, and sympathetic activation, leading to vasodilation, reduced sodium and water retention, and ultimately lower arterial pressure. The effect is dose‑dependent and contributes to improved endothelial function and reduced cardiac afterload.

Olmesartan Vocate may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate intensity, often transient.
• Fatigue: feeling of tiredness without exertion.
• Upper respiratory tract infection: symptoms such as sore throat or nasal congestion.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue or throat, potentially airway‑obstructing.
• Hyperkalemia: elevated blood potassium levels, may cause cardiac rhythm disturbances.
• Acute renal failure: sudden decline in kidney function, indicated by reduced urine output and increased serum creatinine.

When prescribing Olmesartan Vocate, clinicians should consider several precautionary measures to ensure safe use.

• Monitor blood pressure: adjust dose based on therapeutic response.
• Assess renal function: use caution in patients with impaired kidney function.
• Check electrolytes: watch for hyperkalemia, especially when combined with potassium‑sparing agents.
• Avoid in pregnancy: contraindicated due to risk of fetal toxicity.
• Caution with dual blockade: avoid concurrent use with ACE inhibitors or other ARBs.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Olmesartan Vocate can interact with other medicines, influencing its antihypertensive effect or safety profile.

Major Interactions (Avoid)

• Aliskiren (in diabetes): combined use may increase risk of renal impairment, hyperkalemia, and hypotension.
• Potassium supplements or potassium‑sparing diuretics: may precipitate dangerous hyperkalemia.
• Lithium: concurrent use can raise lithium concentrations, leading to toxicity.

Moderate Interactions (Monitor Closely)

• NSAIDs: may attenuate the blood‑pressure‑lowering effect of olmesartan.
• Thiazide diuretics: can enhance hypotensive response and affect electrolyte balance.
• ACE inhibitors: additive blood pressure reduction and potential for renal dysfunction; monitor renal function and electrolytes.